Antidiabetics – GLP-1 Agonists

Medical policy no. 27.17.00-1          Effective Date:  February 1, 2022

Note: New-to-market drugs included in this class based on the Apple Health Preferred Drug List are non-preferred and subject to this prior authorization (PA) criteria. Non-preferred agents in this class require an inadequate response or documented intolerance due to severe adverse reaction or contraindication to at least TWO preferred agents. If there is only one preferred agent in the class documentation of inadequate response to ONE preferred agent is needed. If a drug within this policy receives a new indication approved by the Food and Drug Administration (FDA), medical necessity for the new indication will be determined on a case-by-case basis following FDA labeling.

Background:
Glucagon-like peptide 1 (GLP-1) agonists, also called incretin mimetics, are used for the treatment of type 2 diabetes. GLP-1 causes the pancreas to produce more insulin after eating and helps keep blood glucose levels within the normal range. GLP-1 agonists mimic the action of GLP-1 made by the body and can affect glucose control through several mechanisms including enhancement of glucose-dependent insulin secretin, slowed gastric emptying, and reduction of postprandial glucagon and food intake.

Medical necessity

<table>
<thead>
<tr>
<th>Drug</th>
<th>Medical Necessity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dulaglutide (Trulicity)</td>
<td>GLP-1 agonists may be considered medically necessary in patients who meet the criteria described in the clinical policy below.</td>
</tr>
<tr>
<td>Exenatide (Byetta)</td>
<td>Preferred GLP-1 agonists do not require prior authorization. To see the list of the current Preferred and Non-Preferred products on the Apple Health Preferred Drug List (AHPDL), please visit: <a href="https://www.hca.wa.gov/assets/billers-and-providers/apple-health-preferred-drug-list.xlsx">https://www.hca.wa.gov/assets/billers-and-providers/apple-health-preferred-drug-list.xlsx</a></td>
</tr>
<tr>
<td>Exenatide Extended Release (Bydureon BCise)</td>
<td></td>
</tr>
<tr>
<td>Liraglutide (Victoza)</td>
<td></td>
</tr>
<tr>
<td>Lixisenatide (Adlyxin)</td>
<td></td>
</tr>
<tr>
<td>Semaglutide subcutaneous, tablet (Ozempic, Rybelsus)</td>
<td></td>
</tr>
</tbody>
</table>

Clinical policy:

<table>
<thead>
<tr>
<th>Clinical Criteria</th>
<th>Non-Preferred GLP-1 Agonists may be approved when all of the following criteria are met:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 Diabetes Mellitus</td>
<td>1. Diagnosis of Type 2 diabetes; <strong>AND</strong></td>
</tr>
<tr>
<td></td>
<td>2. The patient meets the appropriate age limit for the requested product (either a or b):</td>
</tr>
<tr>
<td></td>
<td>a) For dulaglutide, lixisenatide, semaglutide: 18 years of age or older; <strong>AND</strong></td>
</tr>
<tr>
<td></td>
<td>b) For exenatide (extended release): 10 years of age or older; <strong>AND</strong></td>
</tr>
</tbody>
</table>

Policy: Antidiabetics - GLP1 Agonists          Medical Policy No. 27.17.00-1          Last Updated 10/27/2021
3. Documentation of HbA1c ≥ 6.5 measured within the past 12 months; **AND**

4. History of failure, defined as inability to achieve glycemic control; intolerance; contraindication or clinically inappropriate to **ALL (a-c)** of the following used separately or simultaneously for a minimum of 90 days:
   a. Metformin at maximum or highest tolerated dose
   b. One preferred SGLT2 inhibitor
   c. One preferred GLP-1

If all the above criteria are met, the request will be approved for **12 months**.

If all criteria are not met, but there are documented medically necessary or situational circumstances, based on the professional judgement of the clinical reviewer, requests may be approved on a case-by-case basis up to the initial authorization duration.

### Criteria (Reauthorization)

1. Documentation showing HbA1c has improved from baseline

If all the above criteria are met, the request will be approved for **12 months**.

If all criteria are not met, but there are documented medically necessary or situational circumstances, based on the professional judgement of the clinical reviewer, requests may be approved on a case-by-case basis up to the reauthorization duration.

**Patients with Type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors who are at risk for major adverse cardiovascular events**

Non-Preferred GLP-1 Agonists may be approved when all of the following criteria are met:

1. Diagnosis of Type 2 diabetes; **AND**
2. Patient has established atherosclerotic cardiovascular disease (ASCVD) or risk factors (see Appendix below); **AND**
3. Documentation of HbA1c ≥ 6.5 measured within the past 12 months; **AND**
4. History of failure, defined as inability to achieve glycemic control; intolerance; contraindication or clinically inappropriate to **ALL (a and b)** of the following used separately or simultaneously for a minimum of 90 days:
   a. One preferred SGLT2 inhibitor; **AND**
   b. Liraglutide

If all the above criteria are met, the request will be approved for **12 months**.
If all criteria are not met, but there are documented medically necessary or situational circumstances, based on the professional judgement of the clinical reviewer, requests may be approved on a case-by-case basis up to the initial authorization duration.

Criteria (Reauthorization)

1. Documentation showing positive clinical response

If all the above criteria are met, the request will be approved for 12 months.

If all criteria are not met, but there are documented medically necessary or situational circumstances, based on the professional judgement of the clinical reviewer, requests may be approved on a case-by-case basis up to the reauthorization duration.

Appendix

ASCVD Defined As:

- Coronary heart disease
  - Myocardial infarction
  - Angina
  - Coronary artery disease
- Cerebrovascular disease
  - Transient ischemic attack
  - Ischemic stroke
- Peripheral artery disease
- Aortic atherosclerotic disease

Cardiovascular Risk Factors include (but not limited to):

- Dyslipidemia
- Hypertension
- Current tobacco use
- Obesity/overweight
- Family history of premature ASCVD
- Chronic kidney disease
- Metabolic syndrome
- Presence of albuminuria

Dosage and quantity limits

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dose and Quantity Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dulaglutide (TRULICITY)</td>
<td>• 18 mg per 30 days</td>
</tr>
<tr>
<td>Exenatide Extended Release (BYDUREON BCISE)</td>
<td>• 8 mg per 30 days</td>
</tr>
<tr>
<td>Lixisenatide (ADLYXIN)</td>
<td>• 600 mcg per 30 days</td>
</tr>
<tr>
<td>Semaglutide subcutaneous (OZEMPIC)</td>
<td>• 4 mg per 30 days</td>
</tr>
<tr>
<td>Semaglutide tablet (RYBELSUS)</td>
<td>• 420 mg per 30 days</td>
</tr>
</tbody>
</table>

References

2. Bydureon (exenatide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2020.
7. Trulicity (dulaglutide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; April 2021.

<table>
<thead>
<tr>
<th>Date</th>
<th>Action and Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/14/2021</td>
<td>New policy created</td>
</tr>
<tr>
<td>08/18/2021</td>
<td>Approved by DUR Board</td>
</tr>
<tr>
<td>09/02/2021</td>
<td>Added established cardiovascular disease or risk of cardiovascular disease in patients with Type 2 diabetes indication</td>
</tr>
</tbody>
</table>